

# ERRATA and CLARIFICATIONS

## TB Message Mapping Guide Dated 8/17/2007

### Notification Structure Tab

#### OID given for Condition Code is incorrect

INV169, PHIN identifier for the condition code that maps to OBR-31: "Default value in each OBR instance: "10220^Tuberculosis^2.16.840.1.114222.4.5.277" should be "Default value in each OBR instance: "10220^Tuberculosis^2.16.840.1.114222.4.5.277"

#### MSH-21 Message Profile ID Clarification

Previous version did not describe values to use for profile identifiers. This clarification has been incorporated in the new version.

The values for the first instance in MSH-21:

NND\_ORU\_v1.0^PHIN^2.16.840.1.114222.4.10.3^ISO

The values for the second instance in MSH-21:

TB\_Case\_Map\_v1.0^PHIN^2.16.840.1.114222.4.10.4^ISO

### Data Element Index and TB Obs. Tabs:

There are some entries in the Description, Valid Values, and Data Validation columns that exceed the number of characters that can appear in the cell. The content is there but it will not appear on a printout. The known affected entries are listed below:

- a. TB203, Description & Data Validation
- b. TB105, Valid Values
- c. TB106, Valid Values
- d. TB111, Valid Values
- e. TB154 Description, Data Validation

### Subject-Related Tab:

DEM113 Current Sex, which maps to PID-8 Administrative Sex, is not used.

DEM114 Birth Sex is the concept that is requested. Birth Sex is passed as an observation under the OBR|1|, which identifies the Subject Type and carries additional subject-related observations that do not map to the PID segment.

### Data Element Index and TB Obs. Tab:

TB202 Estimated US Entry Date Indicator - the description should be "This indicator set to "true" if date the patient entered the US was estimated."

### EXAMPLE Tab

*Removed observations not supported by TB that were in the sample message.*

*MSH-21 had been truncated and was corrected*

*Re-sequenced the OBX segments.*

### SAMPLE MESSAGE CLEANUP:

```
MSH|^~\&|^2.16.840.1.114222.4.5.232.1.xxx^ISO|^2.16.840.1.114222.4.5.232.1.150^
ISO|^2.16.840.1.114222.4.3.2.3^ISO|^2.16.840.1.114222^ISO|200701310921100||ORU^
R01^ORU_R01|NOT0501065111|D|2.5|||NND_ORU_v1.0^PHIN^2.16.840.1.114222.4.1
0.3^ISO~TB_Case_Map_v1.0^PHIN^2.16.840.1.114222.4.10.4^ISO<CR>
```

## ERRATA and CLARIFICATIONS

PID|1||<DEM197 value>^^&<OID>&ISO|~^S|19671206|||1002-5^American Indian or Alaska Native^2.16.840.1.113883.6.238^I^Indian^L~2106-3^White^2.16.840.1.113883.6.238^C^Caucasian^L|||2135-2^Hispanic or Latino^2.16.840.1.113883.6.238^H^Hispanic^L|||KY^CAYMAN ISLANDS^2.16.1<CR>  
OBR|1|""|<INV168 value>^^OID^ISO|PERSUBJ^Person  
Subject^2.16.840.1.114222.4.5.274|||200606010191310|||200606010191310|||F|||10220^Tuberculosis^2.16.840.1.114222.4.5.277<CR>  
OBX|1|CWE|DEM153^Detailed Race^2.16.840.1.114222.4.5.232||1002-5^American Indian or Alaska Native^I^Indian^L~1047-0^Cabazon^2.16.840.1.113883.6.238~1051-2^Torres-Martinez^2.16.840.1.113883.6.238|||F<CR>  
OBX|2|CWE|DEM156^Detailed Ethnicity^2.16.840.1.114222.4.5.232||2153-5^Mexican American Indian^2.16.840.1.113883.6.238~2155-0^Central American^2.16.840.1.113883.6.238|||F<CR>  
OBX|3|IS|DEM2003^US Citizen^2.16.840.1.114222.4.5.232|F|||F<CR>  
OBX|4|TS|DEM2006^Date of Entry in US^2.16.840.1.114222.4.5.232|2000|||F<CR>  
OBX|5|CWE|DEM114^Birth  
Sex^2.16.840.1.114222.4.5.232|M^Male^2.16.840.1.113883.12.1|||F<CR>  
OBR|2|""|<INV168 value>^^OID^ISO|NOTF^Case  
Notification^2.16.840.1.114222.4.5.274|||200606010191310|||200606010191310|||F|||10220^Tuberculosis^2.16.840.1.114222.4.5.277<CR>  
OBX|1|CWE|NOT109^Reporting  
State^2.16.840.1.114222.4.5.232||13^Georgia^2.16.840.1.113883.6.92|||F<CR>  
OBX|2|IS|TB202^Estimated US Entry Date  
Indicator^2.16.840.1.114222.4.5.232|T|||F<CR>  
OBX|3|CWE|TB203^RVCT Status^2.16.840.1.114222.4.5.232|C0422202^Notification, NOS^2.16.840.1.113883.6.96^N^Notified^L|||F<CR>  
OBX|4|TS|INV111^Report Date^2.16.840.1.114222.4.5.232|20060805|||F<CR>  
OBX|5|TS|INV147^Investigation Start  
Date^2.16.840.1.114222.4.5.232|20060718|||F<CR>  
OBX|6|SN|INV165^MMWR Week^2.16.840.1.114222.4.5.232|^23|||F<CR>  
OBX|7|TS|INV166^MMWR Year^2.16.840.1.114222.4.5.232|2006|||F<CR>  
OBX|8|ST|INV172^Patient Chart  
Number^2.16.840.1.114222.4.5.232|LocalPatientID|||F<CR>  
OBX|9|ST|INV173^State Case ID^2.16.840.1.114222.4.5.232|StateCaseID|||F<CR>  
OBX|10|ST|TB098^Investigation Submitted By^2.16.840.1.114222.4.5.232|NAME OF INVESTIGATOR AS STRING|||F<CR>  
OBX|11|CWE|TB099^Inside city  
limits^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||F<CR>  
OBX|12|TS|TB100^Date Counted^2.16.840.1.114222.4.5.232|20060802|||F<CR>  
OBX|13|CWE|TB101^Status at Diagnosis of  
TB^2.16.840.1.114222.4.5.232||81323004^Normal general body  
function^2.16.840.1.113883.6.96^A^Alive^L|||F<CR>  
OBX|14|CWE|TB102^Previous Diagnosis of  
TB^2.16.840.1.114222.4.5.232|Y^Yes^2.16.840.1.113883.12.136|||F<CR>  
OBX|15|TS|TB103^Year of Previous  
Diagnosis^2.16.840.1.114222.4.5.232|2000|||F<CR>  
OBX|16|IS|TB104^More than One Previous  
Episode^2.16.840.1.114222.4.5.232|T|||F<CR>  
OBX|17|CWE|TB105^Major Site of  
Disease^2.16.840.1.114222.4.5.232||1231004^Meninges  
structure^2.16.840.1.113883.6.96^MN^Meningeal^L|||F<CR>  
OBX|18|CWE|TB106^Additional Site of  
Disease^2.16.840.1.114222.4.5.232||10200004^Liver  
structure^2.16.840.1.113883.6.96~12738006^Brain  
structure^2.16.840.1.113883.6.96~110708006^Middle ear AND mastoid  
cells^2.16.840.1.113883.6.96|||F<CR>

## ERRATA and CLARIFICATIONS

OBX|19|IS|TB107^More Than One Additional Site  
Indicator^2.16.840.1.114222.4.5.232||T|||||F<CR>  
OBX|20|CWE|TB108^Sputum  
Smear^2.16.840.1.114222.4.5.232||10828004^Positive^2.16.840.1.113883.6.96^P^Po  
sitive^L|||||F<CR>  
OBX|21|CWE|TB109^Sputum  
Culture^2.16.840.1.114222.4.5.232||10828004^Positive^2.16.840.1.113883.6.96^P^P  
ositive^L|||||F<CR>  
OBX|22|CWE|TB110^Microscopic Exam of Tissue and Other Body  
Fluids^2.16.840.1.114222.4.5.232||10828004^Positive^2.16.840.1.113883.6.96^P^Po  
sitive^L|||||F<CR>  
OBX|23|CWE|TB111^Microscopic Exam Site  
1^2.16.840.1.114222.4.5.232||55214000^Bronchiole  
structure^2.16.840.1.113883.6.96|||||F<CR>  
OBX|24|CWE|TB112^Microscopic Exam Site  
2^2.16.840.1.114222.4.5.232||3120008^Pleural  
structure^2.16.840.1.113883.6.96|||||F<CR>  
OBX|25|CWE|TB113^Culture of Tissue and Other Body  
Fluids^2.16.840.1.114222.4.5.232||10828004^Positive^2.16.840.1.113883.6.96^P^Po  
sitive^L|||||F<CR>  
OBX|26|CWE|TB114^Culture Site 1^2.16.840.1.114222.4.5.232||258446004^Bronchial  
fluid sample^2.16.840.1.113883.6.96|||||F<CR>  
OBX|27|CWE|TB115^Culture Site 2^2.16.840.1.114222.4.5.232||PHC6^Multiple Body  
Sites^2.16.840.1.113883.6.96|||||F<CR>  
OBX|28|CWE|TB116^Chest XRay Results^2.16.840.1.114222.4.5.232||A^Abnormal  
(applies to non-numeric  
results^2.16.840.1.113883.12.78^ABN^ABNORMAL^L|||||F<CR>  
OBX|29|CWE|TB117^Abnormal Chest X-ray Cavitory  
Status^2.16.840.1.114222.4.5.232||C0239013^Chest Xray Cavitory  
Lesion^2.16.840.1.113883.6.86^EYH044^Cavitory^L|||||F<CR>  
OBX|30|CWE|TB118^Abnormal Chest X-ray Condition  
Status^2.16.840.1.114222.4.5.232||230993007^Worsening^2.16.840.1.113883.6.96|||  
||F<CR>  
OBX|31|CWE|TB119^Skin Test at  
Diagnosis^2.16.840.1.114222.4.5.232||10828004^Positive^2.16.840.1.113883.6.96^P  
^POSITIVE^L|||||F<CR>  
OBX|32|SN|TB120^Millimeters of  
Induration^2.16.840.1.114222.4.5.232||^9|||||F<CR>  
OBX|33|CWE|TB121^Was Patient  
Anergic^2.16.840.1.114222.4.5.232||Y^Yes^2.16.840.1.113883.12.136|||||F<CR>  
OBX|34|CWE|TB122^HIV  
Status^2.16.840.1.114222.4.5.232||10828004^POSITIVE^2.16.840.1.113883.6.96^P^PO  
SITIVE^L|||||F<CR>  
OBX|35|CWE|TB123^HIV Based On^2.16.840.1.114222.4.5.232||107729005^Chart  
evaluation, medical records  
perspective^2.16.840.1.113883.6.96^107729005|Medical Documentation^L|||||F<CR>  
OBX|36|ST|TB124^CDC AIDS Patient  
Number^2.16.840.1.114222.4.5.232||CDCPtNumberString|||||F<CR>  
OBX|37|ST|TB125^State AIDS Patient  
Number^2.16.840.1.114222.4.5.232||StateHIVAidsPtNumberString|||||F<CR>  
OBX|38|ST|TB126^City County AIDS Patient  
Number^2.16.840.1.114222.4.5.232||CITYPtNumberString|||||F<CR>  
OBX|39|CWE|TB127^Homeless Within Past  
Year^2.16.840.1.114222.4.5.232||Y^Yes^2.16.840.1.113883.12.136|||||F<CR>  
OBX|40|CWE|TB128^Resident of Correctional Facility at Time of  
Diagnosis^2.16.840.1.114222.4.5.232||Y^Yes^2.16.840.1.113883.12.136|||||F<CR>

## ERRATA and CLARIFICATIONS

OBX|41|CWE|TB129^Type of Correctional Facility^2.16.840.1.114222.4.5.232|PHC46^Federal Prison^2.16.840.1.114222.4.5.274^003^Federal Prison^L|||||F<CR>

OBX|42|CWE|TB130^Resident of Long Term Care Facility at Time of Diagnosis^2.16.840.1.114222.4.5.232|Y^Yes^2.16.840.1.113883.12.136|||||F<CR>

OBX|43|CWE|TB131^Type of Long-Term Care Facility^2.16.840.1.114222.4.5.232|282E00000X^Long Term Care Hospital^2.16.840.1.113883.5.53^32074000^Long-Term Care Facility|||||F<CR>

OBX|44|CWE|TB132^Isoniazid Initial Regimen^2.16.840.1.114222.4.5.232|Y^Yes^2.16.840.1.113883.12.136|||||F<CR>

OBX|45|CWE|TB133^Rifampin Initial Regimen^2.16.840.1.114222.4.5.232|Y^Yes^2.16.840.1.113883.12.136|||||F<CR>

OBX|46|CWE|TB134^Pyrazinamide Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|47|CWE|TB135^Ethambutol Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|48|CWE|TB136^Streptomycin Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|49|CWE|TB137^Ethionamide Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|50|CWE|TB138^Kanamycin Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|51|CWE|TB139^Cycloserine Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|52|CWE|TB140^Capreomycin Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|53|CWE|TB141^Para-Amino Salicylic Acid Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|54|CWE|TB142^Amikacin Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|55|CWE|TB143^Rifabutin Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|56|CWE|TB144^Ciprofloxacin Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|57|CWE|TB145^Ofloxacin Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|58|CWE|TB146^Other Initial Regimen^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|59|TS|TB147^Date Therapy Started^2.16.840.1.114222.4.5.232|20060415|||||F<CR>

OBX|60|CWE|TB148^Injecting Drug Use Within Past Year^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|61|CWE|TB149^Non-Injecting Drug Use Within Past Year^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|62|CWE|TB150^Excess Alcohol Use Within Past Year^2.16.840.1.114222.4.5.232|Y^Yes^2.16.840.1.113883.12.136|||||F<CR>

OBX|63|CWE|TB151^Employment Status^2.16.840.1.114222.4.5.232|224363007^Employed^2.16.840.1.113883.6.96^E^EMPLOYED^L|||||F<CR>

OBX|64|CWE|TB152^Occupation Risk Category^2.16.840.1.114222.4.5.232|C0018724^Health Care Worker^2.16.840.1.113883.6.86~PHC60^Migratory Agricultural Worker^2.16.840.1.114222.4.5.274|||||F<CR>

OBX|65|CWE|TB153^Count at CDC as Verified^2.16.840.1.114222.4.5.232|Y^Yes^2.16.840.1.113883.12.136|||||F<CR>

OBX|66|CWE|TB154^Case Verification^2.16.840.1.114222.4.5.232|PHC97^Positive Culture^2.16.840.1.114222.4.5.274^1POSCULT^1-Positive Culture^1|||||F<CR>

## ERRATA and CLARIFICATIONS

OBX|67|CWE|TB156^Was Drug Susceptibility Testing  
Done^2.16.840.1.114222.4.5.232|Y^Yes^2.16.840.1.113883.12.136|||||F<CR>

OBX|68|TS|TB157^Date First Isolate  
Collected^2.16.840.1.114222.4.5.232|20060414|||||F<CR>

OBX|69|CWE|TB158^Isoniazid Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|70|CWE|TB159^Rifampin Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|71|CWE|TB160^Pyrazinamide Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|72|CWE|TB161^Ethambutol Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|73|CWE|TB162^Streptomycin Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|74|CWE|TB163^Ethionamide Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|75|CWE|TB164^Kanamycin Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|76|CWE|TB165^Cycloserine Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|77|CWE|TB166^Capreomycin Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|78|CWE|TB167^Para-Amino Salicylic Acid Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|79|CWE|TB168^Amikacin Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|80|CWE|TB169^Rifabutin Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|81|CWE|TB170^Ciprofloxacin Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|82|CWE|TB171^Ofloxacin Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|83|CWE|TB172^Other Initial  
Susceptibility^2.16.840.1.114222.4.5.232|S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78>|||||F<CR>

OBX|84|CWE|TB173^Culture Conversion  
Documented^2.16.840.1.114222.4.5.232|N^No^2.16.840.1.113883.12.136|||||F<CR>

OBX|85|TS|TB174^Date Initial Positive  
Culture^2.16.840.1.114222.4.5.232|20060415|||||F<CR>

OBX|86|TS|TB175^Date First Consistently Negative  
Culture^2.16.840.1.114222.4.5.232|20060630|||||F<CR>

OBX|87|TS|TB176^Date Therapy  
Stopped^2.16.840.1.114222.4.5.232|20060704|||||F<CR>

## ERRATA and CLARIFICATIONS

OBX|88|CWE|TB177^Reason Therapy  
Stopped^2.16.840.1.114222.4.5.232||183948000^Uncooperative or  
refused^2.16.840.1.113883.6.96^REFUSED^Refused procedure - parent's  
wish^L|||||F<CR>

OBX|89|CWE|TB178^Type of Health Care Provider^2.16.840.1.114222.4.5.232||PCH23^  
Both Health Dept and Private/Other^2.16.840.1.114222.4.5.274^BOTH^Both Health  
Dept and Private/Other^L|||||F<CR>

OBX|90|CWE|TB179^Directly Observed  
Therapy^2.16.840.1.114222.4.5.232||PHC140^Yes, Both DOT and Self-  
Administered^2.16.840.1.114222.4.5.274^Y2^Yes, Both DOT and Self-  
Administered^L|||||F<CR>

OBX|91|CWE|TB180^Site(s) of Directly Observed  
Therapy^2.16.840.1.114222.4.5.232||PHC19^In clinic or other  
facility^2.16.840.1.114222.4.5.274^C^CLINIC^L~FLD^In the  
field^2.16.840.1.113883.5.4^F^FIELD^L|||||F<CR>

OBX|92|SN|TB181^Number of Weeks of Directly Observed  
Therapy^2.16.840.1.114222.4.5.232|^5|||||F<CR>

OBX|93|CWE|TB182^Follow-Up Susceptibility  
Testing^2.16.840.1.114222.4.5.232||Y^Yes^2.16.840.1.113883.12.136|||||F<CR>

OBX|94|TS|TB183^Follow-Up Susceptibility Testing  
Date^2.16.840.1.114222.4.5.232||20060701|||||F<CR>

OBX|95|CWE|TB184^Isoniazid Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|96|CWE|TB185^Rifampin Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|97|CWE|TB186^Pyrazinamide Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|98|CWE|TB187^Ethambutol Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|99|CWE|TB188^Streptomycin Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|100|CWE|TB189^Ethionamide Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|101|CWE|TB190^Kanamycin Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|102|CWE|TB191^Cycloserine Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|103|CWE|TB192^Capreomycin Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|104|CWE|TB193^Para-Amino Salicylic Acid Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|105|CWE|TB194^Amikacin Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

OBX|106|CWE|TB195^Rifabutin Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>

## ERRATA and CLARIFICATIONS

OBX|107|CWE|TB196^Ciprofloxacin Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>  
OBX|108|CWE|TB197^Ofloxacin Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>  
OBX|109|CWE|TB198^Other Final  
Susceptibility^2.16.840.1.114222.4.5.232||S^Susceptible. Indicates for  
microbiology susceptibilities only.^2.16.840.1.113883.12.78|||||F<CR>  
OBX|110|CWE|TB080^Reporting Address  
City^2.16.840.1.114222.4.5.232||331532^Decatur^2.16.840.1.113883.6.245|||||F<C  
R>  
OBX|111|CWE|TB081^Reporting Address County^2.16.840.1.114222.4.5.232||13135^The  
county of Gwinnett,Georgia^2.16.840.1.113883.6.93|||||F<CR>  
OBX|112|ST|TB082^Reporting Address Zip  
Code^2.16.840.1.114222.4.5.232||30032|||||F<CR>  
OBX|113|CWE|NOT109^Reporting  
State^2.16.840.1.114222.4.5.232||GA^Georgia^2.16.840.1.113883.6.92|||||F<CR>  
OBX|114|IS|TB202^Estimated US Entry Date  
Indicator^2.16.840.1.114222.4.5.232||T|||||F<CR>